Aktuellt
SENASTE
Cantargia's clinical programme is progressing in line with the company's previous communication. The plan to present the CANFOUR results by end-2020 and early 2021 remains in place. Cost development has remained healthy, and even though spending in the coming quarters is contingent on the upcoming clinical results, we argue that the company is well financed until at least 2022. In our view, the upcoming readout from CANFOUR is the next key valuation trigger for the share.
LÄS MER
